Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals preparations, pharmaceutical business, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti-infection products, such as fosfomycin series, azithromycin series, amantadine series, berberine hydroch… Read more
Northeast Pharmaceutical Group Co Ltd (000597) - Net Assets
Latest net assets as of September 2025: CN¥5.60 Billion CNY
Based on the latest financial reports, Northeast Pharmaceutical Group Co Ltd (000597) has net assets worth CN¥5.60 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.65 Billion) and total liabilities (CN¥8.05 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.60 Billion |
| % of Total Assets | 41.01% |
| Annual Growth Rate | 8.45% |
| 5-Year Change | 35.11% |
| 10-Year Change | 131.97% |
| Growth Volatility | 22.74 |
Northeast Pharmaceutical Group Co Ltd - Net Assets Trend (1993–2024)
This chart illustrates how Northeast Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Northeast Pharmaceutical Group Co Ltd (1993–2024)
The table below shows the annual net assets of Northeast Pharmaceutical Group Co Ltd from 1993 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.57 Billion | +7.97% |
| 2023-12-31 | CN¥5.16 Billion | +9.45% |
| 2022-12-31 | CN¥4.71 Billion | +9.86% |
| 2021-12-31 | CN¥4.29 Billion | +4.08% |
| 2020-12-31 | CN¥4.12 Billion | +5.22% |
| 2019-12-31 | CN¥3.92 Billion | +9.05% |
| 2018-12-31 | CN¥3.59 Billion | +41.01% |
| 2017-12-31 | CN¥2.55 Billion | +4.68% |
| 2016-12-31 | CN¥2.43 Billion | +1.37% |
| 2015-12-31 | CN¥2.40 Billion | -13.04% |
| 2014-12-31 | CN¥2.76 Billion | +72.68% |
| 2013-12-31 | CN¥1.60 Billion | -8.64% |
| 2012-12-31 | CN¥1.75 Billion | +0.43% |
| 2011-12-31 | CN¥1.74 Billion | -15.62% |
| 2010-12-31 | CN¥2.07 Billion | +0.58% |
| 2009-12-31 | CN¥2.05 Billion | +30.42% |
| 2008-12-31 | CN¥1.57 Billion | +77.07% |
| 2007-12-31 | CN¥889.22 Million | -4.13% |
| 2006-12-31 | CN¥927.49 Million | +3.05% |
| 2005-12-31 | CN¥900.07 Million | +1.82% |
| 2004-12-31 | CN¥884.02 Million | +1.58% |
| 2003-12-31 | CN¥870.26 Million | -0.35% |
| 2002-12-31 | CN¥873.28 Million | -1.14% |
| 2001-12-31 | CN¥883.36 Million | -2.45% |
| 2000-12-31 | CN¥905.53 Million | +4.12% |
| 1999-12-31 | CN¥869.73 Million | -12.95% |
| 1998-12-31 | CN¥999.14 Million | +6.82% |
| 1997-12-31 | CN¥935.36 Million | -5.95% |
| 1996-12-31 | CN¥994.58 Million | +28.32% |
| 1995-12-31 | CN¥775.11 Million | +59.11% |
| 1994-12-31 | CN¥487.14 Million | +8.00% |
| 1993-12-31 | CN¥451.06 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Northeast Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2781.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.27 Billion | 23.83% |
| Common Stock | CN¥1.43 Billion | 26.85% |
| Other Comprehensive Income | CN¥8.97 Million | 0.17% |
| Other Components | CN¥2.62 Billion | 49.15% |
| Total Equity | CN¥5.32 Billion | 100.00% |
Northeast Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Northeast Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Korea Circuit Co. Ltd.
KO:007810
|
$425.68 Million |
|
Shibaura Machine Co.Ltd
F:TOA
|
$425.90 Million |
|
Olectra Greentech Limited
NSE:OLECTRA
|
$425.95 Million |
|
Cooper-Standard Holdings Inc
F:C31
|
$426.10 Million |
|
CARE Ratings Limited
NSE:CARERATING
|
$425.50 Million |
|
Dream Finders Homes Inc
NYSE:DFH
|
$425.42 Million |
|
Suzhou K-Hiragawa Electronic Technology Co. Ltd. A
SHG:603052
|
$425.35 Million |
|
Canaccord Genuity Group Inc
PINK:CCORF
|
$425.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Northeast Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,988,270,000 to 5,321,613,000, a change of 333,343,000 (6.7%).
- Net income of 409,848,501 contributed positively to equity growth.
- Dividend payments of 206,138,041 reduced retained earnings.
- Other comprehensive income increased equity by 564,433.
- Other factors increased equity by 129,068,107.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥409.85 Million | +7.7% |
| Dividends Paid | CN¥206.14 Million | -3.87% |
| Other Comprehensive Income | CN¥564.43K | +0.01% |
| Other Changes | CN¥129.07 Million | +2.43% |
| Total Change | CN¥- | 6.68% |
Book Value vs Market Value Analysis
This analysis compares Northeast Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.99x to 1.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | CN¥0.67 | CN¥5.33 | x |
| 1994-12-31 | CN¥0.72 | CN¥5.33 | x |
| 1995-12-31 | CN¥1.15 | CN¥5.33 | x |
| 1996-12-31 | CN¥1.47 | CN¥5.33 | x |
| 1997-12-31 | CN¥1.38 | CN¥5.33 | x |
| 1998-12-31 | CN¥1.22 | CN¥5.33 | x |
| 1999-12-31 | CN¥1.29 | CN¥5.33 | x |
| 2000-12-31 | CN¥1.29 | CN¥5.33 | x |
| 2001-12-31 | CN¥1.27 | CN¥5.33 | x |
| 2002-12-31 | CN¥1.29 | CN¥5.33 | x |
| 2003-12-31 | CN¥1.29 | CN¥5.33 | x |
| 2004-12-31 | CN¥1.31 | CN¥5.33 | x |
| 2005-12-31 | CN¥1.33 | CN¥5.33 | x |
| 2006-12-31 | CN¥1.38 | CN¥5.33 | x |
| 2007-12-31 | CN¥1.31 | CN¥5.33 | x |
| 2008-12-31 | CN¥2.29 | CN¥5.33 | x |
| 2009-12-31 | CN¥2.73 | CN¥5.33 | x |
| 2010-12-31 | CN¥2.73 | CN¥5.33 | x |
| 2011-12-31 | CN¥2.23 | CN¥5.33 | x |
| 2012-12-31 | CN¥1.85 | CN¥5.33 | x |
| 2013-12-31 | CN¥2.03 | CN¥5.33 | x |
| 2014-12-31 | CN¥3.03 | CN¥5.33 | x |
| 2015-12-31 | CN¥2.17 | CN¥5.33 | x |
| 2016-12-31 | CN¥2.19 | CN¥5.33 | x |
| 2017-12-31 | CN¥2.30 | CN¥5.33 | x |
| 2018-12-31 | CN¥2.86 | CN¥5.33 | x |
| 2019-12-31 | CN¥3.01 | CN¥5.33 | x |
| 2020-12-31 | CN¥3.25 | CN¥5.33 | x |
| 2021-12-31 | CN¥3.07 | CN¥5.33 | x |
| 2022-12-31 | CN¥3.38 | CN¥5.33 | x |
| 2023-12-31 | CN¥3.48 | CN¥5.33 | x |
| 2024-12-31 | CN¥3.72 | CN¥5.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Northeast Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.70%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.46%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 2.71x
- Recent ROE (7.70%) is above the historical average (2.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 9.76% | 4.39% | 0.67x | 3.33x | CN¥-1.09 Million |
| 1994 | 12.98% | 6.76% | 0.58x | 3.28x | CN¥14.51 Million |
| 1995 | 6.08% | 4.49% | 0.43x | 3.16x | CN¥-30.41 Million |
| 1996 | 2.01% | 1.71% | 0.38x | 3.11x | CN¥-79.51 Million |
| 1997 | -7.40% | -9.14% | 0.35x | 2.32x | CN¥-162.78 Million |
| 1998 | 4.31% | 4.67% | 0.29x | 3.14x | CN¥-46.90 Million |
| 1999 | 4.99% | 4.29% | 0.39x | 2.99x | CN¥-43.58 Million |
| 2000 | 2.23% | 1.63% | 0.45x | 3.06x | CN¥-67.73 Million |
| 2001 | 0.44% | 0.27% | 0.52x | 3.20x | CN¥-82.32 Million |
| 2002 | 1.11% | 0.69% | 0.52x | 3.07x | CN¥-77.65 Million |
| 2003 | 1.00% | 0.54% | 0.64x | 2.90x | CN¥-78.34 Million |
| 2004 | 0.68% | 0.37% | 0.67x | 2.75x | CN¥-82.41 Million |
| 2005 | 1.38% | 0.68% | 0.80x | 2.55x | CN¥-77.59 Million |
| 2006 | 2.65% | 1.17% | 0.95x | 2.38x | CN¥-68.16 Million |
| 2007 | 5.36% | 1.28% | 1.21x | 3.44x | CN¥-41.22 Million |
| 2008 | 22.77% | 7.76% | 1.12x | 2.61x | CN¥200.75 Million |
| 2009 | 23.58% | 9.35% | 0.84x | 3.01x | CN¥274.16 Million |
| 2010 | 2.64% | 1.11% | 0.86x | 2.77x | CN¥-148.89 Million |
| 2011 | -23.79% | -10.15% | 0.66x | 3.54x | CN¥-560.00 Million |
| 2012 | 0.49% | 0.21% | 0.64x | 3.60x | CN¥-158.42 Million |
| 2013 | -11.11% | -4.31% | 0.51x | 5.02x | CN¥-317.30 Million |
| 2014 | 3.27% | 2.01% | 0.51x | 3.22x | CN¥-179.36 Million |
| 2015 | -16.79% | -10.02% | 0.44x | 3.80x | CN¥-613.28 Million |
| 2016 | 1.03% | 0.49% | 0.49x | 4.23x | CN¥-207.66 Million |
| 2017 | 4.89% | 2.10% | 0.54x | 4.35x | CN¥-124.37 Million |
| 2018 | 5.62% | 2.61% | 0.64x | 3.38x | CN¥-151.88 Million |
| 2019 | 4.57% | 2.12% | 0.66x | 3.29x | CN¥-207.10 Million |
| 2020 | 0.31% | 0.17% | 0.61x | 3.06x | CN¥-385.80 Million |
| 2021 | 2.39% | 1.22% | 0.62x | 3.18x | CN¥-315.35 Million |
| 2022 | 7.68% | 3.98% | 0.64x | 3.03x | CN¥-105.68 Million |
| 2023 | 7.19% | 4.35% | 0.54x | 3.06x | CN¥-140.37 Million |
| 2024 | 7.70% | 5.46% | 0.52x | 2.71x | CN¥-122.31 Million |
Industry Comparison
This section compares Northeast Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,256,935,492
- Average return on equity (ROE) among peers: -0.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Northeast Pharmaceutical Group Co Ltd (000597) | CN¥5.60 Billion | 9.76% | 1.44x | $425.60 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |